4//SEC Filing
Bellerophon Therapeutics, Inc. 4
Accession 0001104659-15-013146
CIK 0001600132operating
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 9:41 PM ET
Size
4.9 KB
Accession
0001104659-15-013146
Insider Transaction Report
Form 4
Luehring Jens
Director10% Owner
Transactions
- Purchase
Common Stock
2015-02-19$12.00/sh+358,916$4,306,992→ 1,629,804 total(indirect: See footnote)
Footnotes (1)
- [F1]These shares are owned directly by Linde North America, Inc. ("Linde"). Jens Luehring is a director and chief financial officer of Linde. Mr. Luehring disclaims beneficial ownership of all shares held by Linde, except to the extent of his pecuniary interest therein.
Documents
Issuer
Bellerophon Therapeutics, Inc.
CIK 0001600132
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001600132
Filing Metadata
- Form type
- 4
- Filed
- Feb 22, 7:00 PM ET
- Accepted
- Feb 23, 9:41 PM ET
- Size
- 4.9 KB